| Ticker |
PRME
|
| CIK | 0001894562 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 60 FIRST ST., CAMBRIDGE, MA, 02141 |
| Website | primemedicine.com |
| Phone | 617-465-0013 |
| CEO | Keith M. Gottesdiener |
| Employees | N/A |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash RunwayPrime Medicine Inc. (NASDAQ:PRME) is one of the best new penny stocks to buy. On March 3, Prime Medicine reported its full-year 2025 financial results, highlighting a shift toward its in vivo liver franchise. The company ended the year with $191.4 million in cash, cash equivalents, and investments, providing a financial runway into 2027. Despite […] Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue EstimatesPrime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment -- -- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 -- CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company Prime Medicine to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: TD Cowen 46th Annual Health Care Conference: Fireside chat on Wednesday, March 4, 2026, at 1:10 p.m. ET in Boston, MA.2026 Jefferies Biotech on the Beach Summit: Company management will host 1x1 meetings on T Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy CompanyJacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in November. Although overall economic growth has been robust throughout the year, recent divergent data on consumer spending and the labor market have put doubt on future […] |
